Levetiracetam Injection, Solution, Concentrate
Product Images NDC 68094-313

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68094-313). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Precision Dose, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A bar graph showing the percentage of patients responding to different treatments. It compares Placebo (7.4%), Levetiracetam 1,000 mg/day (37.1%), and Levetiracetam 3,000 mg/day (39.6%). The y-axis represents the percentage of patients, and each bar is labeled with treatment details and sample size.*

FDA Label Image

Figure 2 (Image 02)

A bar chart displaying the percentage of patients in three groups: placebo (6.3%), levetiracetam 1,000 mg/day (20.8%), and levetiracetam 2,000 mg/day (35.2%). The y-axis represents the percentage of patients, and the x-axis lists the three treatment groups with sample sizes indicated.*

FDA Label Image

Figure 3 (Image 03)

A bar chart comparing the percentage of patients for placebo and Levetiracetam 3,000 mg/day groups. The y-axis shows percentage of patients from 0% to 45%. The placebo group (N=104) shows 14.4%, while the Levetiracetam group (N=180) shows 39.4%, with an asterisk indicating statistical significance.*

FDA Label Image

Figure 4 (Image 04)

A bar chart comparing the percentage of patients between a placebo group (19.6%) and a levetiracetam group (44.6%). The x-axis shows the two groups labeled as Placebo (N=97) and Levetiracetam (N=101), and the y-axis represents the percentage of patients ranging from 0% to 45%.*

FDA Label Image

Figure 5 (Image 05)

A bar chart comparing the percentage of patients for two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The y-axis represents the percentage of patients from 0% to 45%. The Levetiracetam bar includes an asterisk indicating statistical significance or a notable difference.*

FDA Label Image

Figure 6 (Image 06)

A bar graph comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The vertical axis shows percent of patients from 0% to 100%, illustrating a higher patient percentage for the Levetiracetam group compared to placebo.*

FDA Label Image

Principal Display Panel (100 mg/mL Vial Carton)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous solution concentrate. The box contains 10 single-dose 5 mL vials. The label includes directions that the drug is sterile and must be diluted prior to administration. Manufactured for Precision Dose, Inc.*

FDA Label Image

Principal Display Panel (100 mg/mL Vial Carton)

Packaging label for Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) injection, concentrate for intravenous use. The box contains 25 single-dose 5 mL vials. Labeler is Precision Dose, Inc., South Beloit, IL. The label includes usage instructions stating the solution must be diluted prior to administration and is sterile, for prescription use only.*

FDA Label Image

Chemical Structure (Levetiracetam)

Chemical structure diagram of levetiracetam, showing its molecular framework with labeled bonds and functional groups consistent with its known chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.